In industrialized nations, the prevalence of IgE-mediated food allergy and anaphylaxis has grown quickly, and countries with fast industrialization may follow. Treatment options include elimination diets, oral immunotherapy, and biologic delivery, although high blood IgE levels may prohibit their use. As a result, lowering IgE levels becomes a viable option, which may be accomplished by immune apheresis. The purpose of this review is to assess the rationale and benefits of immune apheresis. The vast majority of available adsorbers remove all types of immunoglobulins. IgE-specific adsorbers were recently authorized. Immunoapheresis data for the treatment of allergic disorders with pathologically high IgE levels are becoming available. This medication appears to be effective on its own in the treatment of atopic dermatitis. IgE-selective apheresis appears to be adequate to minimize the risk of anaphylaxis in multiple food allergies (MFA) and, when IgE titers are high, to pave the way for Omalizumab therapy.
To examine the efficacy, acceptability, and cost-effectiveness of immunoapheresis in the field of food allergy, prospective trials with well-designed procedures are required.